Therapeutic carbohydrate restriction and sodium-glucose transporter 2 inhibitors in chronic kidney disease: A potentially powerful combination

Diabetes Obes Metab. 2023 Oct;25(10):2791-2794. doi: 10.1111/dom.15195. Epub 2023 Jun 29.

Authors

Karen M Dwyer¹, Penny Figtree², Alok Gupta³

Affiliations

¹ School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
² UNSW Medicine & Health, School of Clinical Medicine, Port Macquarie, New South Wales, Australia.
³ Darling Downs Health, Toowoomba, Queensland, Australia.

PMID: 37385954
DOI: 10.1111/dom.15195

No abstract available

Keywords: SGLT2 inhibitor; diabetic nephropathy; drug mechanism; effectiveness; type 2 diabetes.

MeSH terms

Carbohydrates / therapeutic use
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetic Nephropathies* / drug therapy
Glucose / therapeutic use
Humans
Kidney
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Carbohydrates
Glucose